Assembly Biosciences Announces Presentation at Jefferies London Healthcare Conference
November 18 2019 - 8:00AM
Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage
biotechnology company developing innovative therapeutics targeting
hepatitis B virus (HBV) and diseases associated with the
microbiome, today announced that John McHutchison, AO, MD, Chief
Executive Officer and President will make a corporate presentation
at the Jefferies London Healthcare Conference on Wednesday,
November 20, 2019 at 9:20am GMT.
A live webcast and replay of the Jefferies presentation will be
available in the Events & Presentations page in the Investors
section of the company's website at assemblybio.com.
About Assembly Biosciences Assembly
Biosciences, Inc. is a clinical-stage biotechnology company
developing innovative therapeutics targeting hepatitis B virus
(HBV) and diseases associated with the microbiome. The HBV program
is focused on advancing a new class of potent, oral core inhibitors
that have the potential to increase cure rates for chronically
infected patients. The microbiome program is developing novel
oral live microbial biotherapeutic candidates with Assembly’s fully
integrated platform, including a robust process for strain
identification and selection, GMP-compliant banking and production,
and targeted delivery to the lower gastrointestinal tract with the
GEMICEL® technology. For more information,
visit assemblybio.com.
Contacts Assembly Biosciences, Inc. Investors:
Lauren Glaser (415) 521-3828 lglaser@assemblybio.com
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Sep 2023 to Sep 2024